Comparison of Radiation Therapy Regimens in Treating Patients With Localized Prostate Cancer
This trial is active, not recruiting.
|Start date||September 1999|
|Trial identifier||NCT00010244, CDR0000068458, EU-20037, FRE-FNCLCC-PAC-GETUG-06-99001|
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of radiation therapy is more effective for prostate cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of radiation therapy in treating patients who have localized prostate cancer.
|United States||No locations recruiting|
|Other Countries||No locations recruiting|
|Bordeaux, France||Hopital Saint Andre||no longer recruiting|
|Dijon, France||Centre de Lute Contre le Cancer,Georges-Francois Leclerc||no longer recruiting|
|Lyon, France||Centre Leon Berard||no longer recruiting|
|Marseille, France||Institut J. Paoli and I. Calmettes||no longer recruiting|
|Metz, France||Hopital Notre-Dame de Bon Secours||no longer recruiting|
|Montpellier, France||Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle||no longer recruiting|
|Nantes-Saint Herblain, France||CRLCC Nantes - Atlantique||no longer recruiting|
|Nice, France||Centre Antoine Lacassagne||no longer recruiting|
|Paris, France||CHU Pitie-Salpetriere||no longer recruiting|
|Paris, France||Institut Curie - Section Medicale||no longer recruiting|
|Pierre Benite, France||Hopital Jules Courmont - Centre Hospitalier Lyon Sud||no longer recruiting|
|Poitiers, France||Hopital Jean Bernard||no longer recruiting|
|Reims, France||Institut Jean Godinot||no longer recruiting|
|Rennes, France||Centre Eugene Marquis||no longer recruiting|
|Rouen, France||Centre Henri Becquerel||no longer recruiting|
|Toulouse, France||Institut Claudius Regaud||no longer recruiting|
|Tours, France||Centre Hospitalier Universitaire Bretonneau de Tours||no longer recruiting|
|Vandoeuvre-les-Nancy, France||Centre Alexis Vautrin||no longer recruiting|
|Villejuif, France||Institut Gustave Roussy||no longer recruiting|
Male participants up to 74 years old.
DISEASE CHARACTERISTICS: Localized prostate cancer: T2a-T3a OR T1b or T1c with PSA at least 10 ng/mL OR T1b or T1c with Gleason score 7-10 No T3b or T4; positive biopsy of nodal excision N0, or any N with bilateral removal and the estimated risk of nodal invasion is at least 10% M0 (by bone scintograph and chest x-ray) PSA less than 50 ng/mL PATIENT CHARACTERISTICS: Age: Under 75 Performance status: WHO 0-1 Life expectancy: At least 10 years Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No other prior invasive malignancy within the past 5 years except basal cell carcinoma No social, familial, or geographic obstacles that would preclude study PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy No concurrent biologic therapy Chemotherapy: No prior chemotherapy No concurrent chemotherapy Endocrine therapy: No prior hormonal therapy including adjuvant therapy No concurrent hormonal therapy Radiotherapy: No prior pelvic radiotherapy Surgery: No prior radical anterior prostatectomy for cancer No prior castration
|Official title||Conformational, Curative Ratiotherapy For Prostate Cancer (NO, N-): Phase III Multicenter Study Of The Contribution To Survival Without Clinical Or Biological Change With A Dose Variation Of 15% (80 Gy VS 70 Gy)|
|Description||OBJECTIVES: I. Compare the 5-year survival rate, in terms of clinical and biological remission, in patients with localized prostate cancer treated with two different radiotherapy regimens using different doses and number of fractions. II. Compare the nadir of PSA and the delay in obtaining the nadir in patients treated with these two regimens. III. Compare acute and long-term toxicity of these two regimens in these patients. IV. Compare overall survival and quality of life in patients treated with these two regimens. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center. Patients are randomized to 1 of 2 treatment arms. Arm I: Patients receive radiotherapy to the seminal vesicles at 46 Gy in 23 fractions and to the prostate at 70 Gy in 35 fractions, with 5 fractions per week. Arm II: Patients receive radiotherapy to the seminal vesicles as in arm I and to the prostate at 80 Gy in 40 fractions, with 5 fractions per week. Treatment continues in both arms in the absence of disease progression or unacceptable toxicity. Quality of life is assessed annually. Patients are followed every 4 months for a minimum of 5 years. PROJECTED ACCRUAL: A total of 306 patients (153 per arm) will be accrued for this study within 2.5 years.|
Call for more information